Fogorvosi szemle, 2006 (99. évfolyam, 1-6. szám)

2006-06-01 / 3. szám

107

FOGORVOSI SZEMLE ■ 99. évf. 3. sz. 2006.

99. Rampes H, Bhandari S: Hypersalivation and lithium toxicity. J Psychopharmacology ‘\994\ 8: 261.

100. Ray SA, Bundy AC, Nelson DL: Decreasing drooling through J techniques to facilitate mouth closure. Am J Occup Ther 1983; 37: | 749-753.

101. Reddihough D, Johnson H, Staples M, Hudson I, Exarchos H: | Use of benzohexol hydrochloride to control drooling of children with | cerebral palsy. Dev Med Child Neurol 1990; 32: 985-989.

102. Reddihough D, Johnson H, Ferguson E:The role of sali va control j clinic in the management of drooling. J Pediatr Child Health 1992;28: 395-397.

103. Rose FC: The management of motor neuron disease. Adv Exp Med S/o/1987; 209: 167-174.

104. Sampaio C, Costa J, Ferreira JJ: Clinical comparability of marketed formulations of botulinum toxin. Mov Dis 2004; 19 (Suppl 8): S129-S136.

105. Schwartz S, Gisel EG, Clarke D, Habenfellner H: Association of occlusion with eating efficiency in children with cerebral palsy and moderate eating impairment. J Dent Child (Chic) 2003; 70: 33-39.

106. Scully C, Cawson RA: Gastrointestinal disease and drug problems in dentistry. In: Scully C, Cawson RA (eds.): Medical Problems in Dentistry. 3rd ed. Wright, Oxford, 1993; 196, 594-595.

107. Senner JE, Logeman J, Zecker S, Gaebler-Spira D: Drooling, saliva production, and swallowing in cerebral palsy. Dev Med Child \ Neurol 2004;46:801-806.

108. De Serpa Pinto MVX, De Magalhäes MHCG, Nunes FD: Moe- | bius syndrome with oral involvement. Int J Pediatr Dent 2002; 12: 446-449.

109. Serrano-Duenas M: Sialorrhoeain patients with Parkinson. A six year postoperative study. Rev Neurol 2003; 37: 623-626.

110. Shannon IL, Chauncey HH: Hyperhydration and parotid flow in man. J Dent Res 1967; 46:1028-1031.

111. Shifman A: Use of complete dentures to stabilize a segmentally resected mandible: a clinical report. J Prosthet Dent 1994; 71: 235-236.

112. Shirley WP, Hill JS, Wooley AL, Wiatrak BJ: Success and J complications for four-duct ligation for sialorrhoea. Int J Pediatr Oto- | rhinolaryngol2003; 67: 1-6.

113. Shott SR, Myer CM, Cotton RD: Surgical management of sia- j lorrhoea. Otolaryngol Head Neck Surg 1989; 101:47-50.

114. Sonnenberg A, Steinkamp U, Weise A, Berges W, Wienbeck M, Rohner HG etal.: Salivary secretion in reflux esophagitis. Gastroenterology 1982; 83: 889-895.

115. Stephen LX, HamersmaH, Gardner J, Beighton P: Dental and oral manifestations of sclerosteosis. Int Dent J 2001 ; 51: 287-290.

116. Sun JG, Wong V, Ma QY, Cheng PW: Pilot study of the use of traditional Chinese medicine (tongue acupuncture) in patients with stable stroke. Proceedings of 13th Annual Scientific Meeting of the Hong Kong Neurological Society Hong Kong 2000; 39.

117. Sungur M, Guven M: Intensive care management of organophosphate insecticide poisoning. Crif Care 2001; 5: 211-215.

118. Suskind DL, Tilton A: Clinical study of botulinum-A toxin in the treatment of sialorrhoea in children with cerebral palsy. Laryngosco- j pe 2002; 112:73-81.

119. Swischuk LE: Cough and drooling for two days. Pediatr Emerg Care 1995; 11: 397-398.

120. Szabadi E, Tavernor S: Hypo- and hypersalivation induced by psychoactive drugs. CNS Drugs 1999; 11: 449-466.

121. Talmi YP, Finkelstein Y, Zohar Y: Reduction of salivary flow with transdermal scopolamine: a four-year experiment. Otolaryngol Head Neck Surg 1990; 103:615-618.

122. Tassinari D, Poggi B, Fantini M, Tamburini E, Sartori S: Treating sialorrhoea with transdermal scopolamine. Exploiting a side effect to treat an uncommon symptom in cancer patients. Support Care Can- | cer 2005; 13:559-561.

123. Thomas-Stonell N, Greenberg J: Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia 1988; 3: 73-78.

124. To R, Wong VCN, Hui Y, Goh WHS, Yung A, Lee C et al.: Pilot study of oro-motor habilitation program for children with drooling

problem: A pilot observation. Hong Kong J Pediat Surg 1999; 4: 96-100.

125. Traube M: The spectrum of the symptoms and presentations of gastroesophageal reflux disease. Gastroenterol North Am 1990; 19: 609-616.

126. Tröster S, Brodmann KF, Schuster HP: Devere digitalis poisoning after ingestion of 1 g of digoxin. Dtsch Med Wochenschr1992; 117: 1149-1152.

127. Tscheng DZ: Sialorrhoea-therapeutic drug options. Ann Pharmacother2002; 36:1785-1790.

128. Turk-Gonzales M, Odderson IR: Quantitative reduction of saliva production with botulinum toxin type B injection into the salivary glands. Neurorehab Neural Repair2005; 19: 58-61.

129. Unal M, Sevim S, Dogu O, Vayisoglu Y, Kanik A: Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: a double-blind placebo-controlled trial. Acta Oto-Laryngol2003; 123: 1060-1063.

130. Vervoon KM, Vissink A: Hypersalivation, lesions of oral mucosa and generalized fatigue. Ned Tijdschr Tandheelk 2000; 107: 522- 524.

131. Wake M, Hesketh K, Lucas J: Teething and tooth eruption in infants: a cohort study. Pediatrics 2000; 106:1374-1379.

132. Wang X, Cheng F, Zhang F, Li XC, Kong LL, Li GQ etal.: Livingrelated liver transplantation for Wilson's disease. Transplant Int2005] 18: 651-656.

133. Warrell DA: The clinical picture of rabies in man. Trans R Soc Trop Med Hyg 1976; 70:188-195.

134. Webber MA, Szwast SJ, Steadman TM, Frazer AMR, Malloy FW, Lightfood JDetal.: Guanfacine treatment of clozapine-induced sialorrhoea. J Clin Pharmacol2004; 24: 675-676.

135. Wilkie TF, Brody GS: The surgical treatment of drooling: a ten year review. Plastic Reconst Surg 1977; 59: 791-797.

136. Winterholler MG, Erbguth FJ, Wolf S, Kat S: Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of a transductal approach. J Neurol Neurosurg Psychiatry 2001; 70: 417-418.

137. Wolff A, Ofer S, Raviv M, Helft M, Cardash HS: The flow rate of whole and submandibular saliva in patients receiving replacement complete dentures. J Oral Rehab 2004; 31: 340-343.

138. Wong V, Sun JG, Wong W: Traditional Chinese medicine (tongue acupuncture) in children with droolinq problems. Pediat Neurol 2001;25:47-54.

139. Wotman S, Mandel ID: Salivary indicators of systemic diseases. Postgrad Med 1973; 53: 73-78.

140. Yam WKL, Yang HLC, Abdullah V, Chan CYL: Management of drooling for children with neurological problems in Hong Kong. Brain Develop2005; 28: 1-6.

141. Yamauchi M, Yotsuyanagi T, Yokoi K, Urushidate S, Yamashita K, Higuma Y: One-stage reconstruction of a large defect of the lower lip and oral commissure. BrJ Plastic Surg 2005; 58: 614-618.

142. Yilmaz S, Basar P, Gisel EG: Assessment of feeding performance in patients with cerebral palsy. Int J Rehabil Res 2004; 27: 325-329.

143. Yotsuyanagi T, Nihei Y, Yokoi K, Sawada Y: Functional reconstruction using a depressor anguli oris musculocutaneous flap for larger lip defects, especially for elderly patients. Plast Reconst Surg 1999; 103:850-856.

144. Yurdukoru B, Terzioglu H, Yilmaz T: Assessment of whole saliva flow rate in denture wearing patients. J Oral Rehabil 2001 ; 28: 109-112.

145. ZavagliaV, NoriA, MansowNM: Longterm effects of palatal plate therapy for the orofacial regulation in children with Down syndrome J Clin Pediatr 2003; 28: 89-93.

146. Zepetalla G: Nebulized scopolamine in the management of oral dribbling: three case reports. J Paint Sympt Manage 1999; 17: 293-295.

147. Zudenigo D, Relja M: Hepatolenticular degeneration. Neurologija 1990; 39:115-127.

148. Zunt S: Severe/frequent recurrent aphthous ulcers and salivary flow rates. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98:197.